AstraZeneca Seeks Full Rehearing Of Generic Drugmaker Win

Law360, Los Angeles (January 21, 2014, 9:23 PM EST) -- AstraZeneca AB on Tuesday asked for a full rehearing before the Federal Circuit in its ongoing efforts to block Hanmi USA Inc.’s generic version of acid reflux drug Nexium, arguing that a Federal Circuit panel disregarded precedent in upholding a lower court’s claim construction.

AstraZeneca argued that the panel erred in deciding that the active ingredient in Hanmi’s drug did not qualify as an alkaline salt as described by AstraZeneca’s patents because those patents only referred to six specific types of salt. Instead of basing its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.